Frontage welcomes Dr. Qi Wei, PhD as Vice President Global Genomic Services
Dr. Qi Wei, PhD, joins Frontage Laboratories Inc as Vice President, Global Genomic Services. Dr. Wei reports directly to Dr. John Lin, PhD, President Global Laboratory Services and will be based in our facility in Ocean Ridge Florida.
Qi (pronounced Chi) brings over three decades of experience in molecular diagnosis in CAP and CLIA environment. He has brought six molecular diagnostics laboratories through CAP and CLIA accreditations since 2018 including a laboratory in Shanghai, China. He was instrumental for the development and implementation of the SARS-CoV-2 RT-PCR testing at Baptist Hospital Miami/Baptist Health South Florida in May, 2020. The assay obtained the FDA-EUA status.
Prior to joining Frontage, Qi served as the vice president of medical affairs and director for the CLIA laboratory at miR Scientific. He successfully brought miR Sentinel Prostate Cancer Test through commercialization and CAP/CLIA accreditation.
Qi served as the Global Subject Matter Expert for oncology and genomics at Philips Healthcare covering North America, EU-7 and APAC markets from 2019 to 2022. During his tenure at Miami Cancer Institute, he was the founding director for genomic laboratory services at Miami Cancer Institute/Baptist Health South Florida where he successfully established and implemented cancer genomic profiling program.
Qi is board certified for molecular pathology by the American Board of Clinical Chemistry. He also holds the clinical laboratory director license for molecular pathology in the State of Florida and the certificate of qualification for molecular pathology in the state of New York. Qi has 30 years’ experience in molecular diagnostics especially cancer genomic profiling for hematologic malignancies and solid tumors. He was the scientific director for molecular diagnostics laboratory at Children’s Hospital Colorado/University of Colorado where he established the molecular testing for genetics, infectious diseases, and cancer profiling.
Qi obtained his PhD in human genetics from the University of Denver, Colorado, and undergraduate study in biochemistry from East China University of Science and Technology, Shanghai, China. His professional credentials include DABC/ Diplomates of American Board of Clinical Chemistry – Molecular Diagnostics and New York State Certificate of Qualification – Molecular Oncology and Cellular Biomarkers.
